RIJSWIJK, The Netherlands and
MENLO PARK, Calif, October 9, 2017 /PRNewswire/ --
Bluebee, a company driving genomic data-driven medicine, and
Pacific Biosciences of California,
Inc. (NASDAQ:PACB), the leader in long-read sequencing, announced
they have integrated the PacBio® de
novo assembly pipeline onto
the Bluebee® genomics analysis
platform. The integration creates a simplified workflow and fully
automated, end-to-end data analysis solution that allows assembly
of any size genome, including the human genome.
Bluebee's platform provides a user-friendly
environment that does not require specialized bioinformatics
knowledge. The solution will be launched next week at the American
Society of Human Genetics (ASHG) annual meeting in Orlando, FL.
"We are continually looking at ways we can help people get more
knowledge and insights from their genomic data, and this
integration of the PacBio de novo assembly pipeline on
the Bluebee genomics analysis platform offers precisely that:
an end-to-end solution with a guaranteed turn-around time, enabling
better planning and improved productivity," said Hans Cobben, CEO of Bluebee. "This will address
the data analysis burden that many people are faced with, and add
both value and convenience to any users of the PacBio de Novo
Assembly Pipeline."
Since parameters can be adjusted within the platform, users can
redefine the pipeline, creating a starting point for further
pipeline developments and optimizations to fit the purpose of
specific use cases.
"With the continuing demand for Single Molecule, Real-Time
(SMRT®) Sequencing in the genomics community, we are
delighted to see this new cloud-based analysis option become
available to users of PacBio data," said Kevin Corcoran, Senior Vice President of Market
Development for PacBio. "The end-to-end solution integrates
downstream data analysis in Bluebee's high-security and
regulatory-compliant compute centers for PacBio customers around
the world."
It is now established that most genomes have high sequence
complexity, encompassing many repetitive elements, copy number
variants, and structural variants. Such complex elements are often
very difficult, if not impossible, to resolve using short-read
technologies.
SMRT Sequencing is the ideal tool to investigate these genetic
complexities, due to its long reads with uniform coverage that
allow comprehensive de novo genome assemblies and provide
more complete and accurate views of all types of genomic
variations. Despite the power of SMRT Sequencing, however, de
novo assembly of large genomes still remains a challenge
requiring, among other things, very powerful compute resources.
The Bluebee platform was designed with confidential sample
information in mind, and thus employs a multi-layered data security
approach to ensure an environment that covers the strictest of
security controls. The Bluebee platform data centers are compliant
with all applicable security and regulatory standards. The
compliance standards Bluebee adheres to include: ISO 27001:2013,
HIPAA, IGT (NHS, UK), C-Star Level 1, PHIPA & PIPEDA
(Canada) and EU Model Clauses
(for regional data storage and processing).
About Bluebee
Bluebee offers a global bio-informatics platform to process,
analyze, share and store genomics data.
With a private cloud service, Bluebee supports users in clinical
diagnostics, therapeutics and research with advanced analytics for
genomic data driven medicine.
Designed for cross-functional teams of clinicians and life
science researchers the Bluebee platform effectively centralizes
and manages genomics data processes and storage. Bluebee's
multi-layered security is designed to meet both specific
organizational and regulatory data protection requirements when
analyzing and storing research or clinical grade data.
Local data processing is guaranteed via "Data Residency
Control" in state-of-the-art data centres. The service is
available across all major European countries and US cities, as
well as in Canada and Asia
Pacific.
Contact Bluebee:
Karen Frost
Karen.frost@bluebee.com
www.bluebee.com
About Pacific Biosciences
Pacific Biosciences of California, Inc. (NASDAQ:PACB) offers
sequencing systems to help scientists resolve genetically complex
problems. Based on its novel Single Molecule, Real-Time (SMRT®)
technology, Pacific Biosciences' products enable: de novo genome
assembly to finish genomes in order to more fully identify,
annotate and decipher genomic structures; full-length transcript
analysis to improve annotations in reference genomes, characterize
alternatively spliced isoforms in important gene families, and find
novel genes; targeted sequencing to more comprehensively
characterize genetic variations; and real-time kinetic information
for epigenome characterization. Pacific Biosciences' technology
provides high accuracy, ultra-long reads, uniform coverage, and the
ability to simultaneously detect epigenetic changes.
PacBio® sequencing systems, including consumables and
software, provide a simple, fast, end-to-end workflow for SMRT
Sequencing. More information is available at www.pacb.com.
Forward-Looking Statements
All statements in this press release that are not historical are
forward-looking statements, including, among other things,
statements relating to future uses, quality or performance of, or
benefits of using, products or technologies, the suitability of
products or technologies for particular applications and other
future events. You should not place undue reliance on
forward-looking statements because they involve known and unknown
risks, uncertainties, changes in circumstances and other factors
that are, in some cases, beyond Pacific Biosciences' control and
could cause actual results to differ materially from the
information expressed or implied by forward-looking statements made
in this press release. Factors that could materially affect actual
results can be found in Pacific Biosciences' most recent filings
with the Securities and Exchange Commission, including Pacific
Biosciences' most recent reports on Forms 8-K, 10-K and 10-Q, and
include those listed under the caption "Risk Factors."
Pacific Biosciences undertakes no obligation to revise or update
information in this press release to reflect events or
circumstances in the future, even if new information becomes
available.
PacBio Contacts:
Media:
Nicole Litchfield
+1-415-793-6468
nicole@bioscribe.com
Investors:
Trevin Rard
+1-650-521-8450
ir@pacificbiosciences.com